Human epidermal growth factor receptor 2 (HER2) protein overexpression and/or HER2
gene amplification is found in about 20% of invasive breast cancers. It is a sole predictive …

Background In metastatic breast cancer, hormone and/or human epidermal growth factor
receptor 2 (HER2)–targeted therapy decision-making is still largely based on tissue …

Background Patients with progressive disease after two or more HER2-directed regimens for
recurrent or metastatic breast cancer have few effective therapeutic options. We aimed to …

Biological changes that occur during metastatic progression of breast cancer are still
incompletely characterized. In this study, we compared intrinsic molecular subtypes and …

Human epidermal growth factor receptor 2 (HER2) status is one of the major tumor
characteristics in breast cancer to guide therapy. Anti-HER2 treatment has clear survival …

Controlling the biodistribution of nanoparticles upon intravenous injection is the key to
achieving target specificity. One of the impediments in nanoparticle-based tumor targeting is …

Intratumoral heterogeneity of human epidermal growth factor receptor 2 (HER2) gene
amplification has been reported to occur with variable frequencies in breast cancers …

Purpose: HER2-positive breast cancer is heterogeneous. Some tumors express mutations,
like activating PIK3CA mutations or reduced PTEN expression, that negatively correlate with …

Predictive biomarkers are becoming increasingly important tools in drug development and
clinical research. The importance of using both guidelines for specimen acquisition and …

Hormone-receptor-positive breast cancer accounts for the majority—up to 80%—of all breast
cancers. The evolution of breast cancer from early stage to the metastatic setting leads to …